Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Wageningen Universiteit manages 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 5 distinct examiners, resulting in a distribution where each case is reviewed by a different individual. This indicates that the university's prosecution is decentralized, with each application following its own independent path.
The 5 pending office actions are distributed across distinct art units, with each case falling into a different specialized group at the patent office. This suggests a broad technical range for the university's current intellectual property filings. Practitioners must navigate the specific requirements and technical nuances of 5 distinct art units while dealing with the assigned examiners.
GOUGH, TIFFANY MAUREEN is the busiest examiner for the portfolio, currently overseeing 1 pending office action. This is consistent with the fact that 5 distinct examiners are handling the pending matters. Without any examiner overlap, the university's legal team must manage independent prosecution tracks, each requiring a unique approach for the specific examiner and art unit assigned.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOUGH, TIFFANY MAUREEN | 1 | 31.6% | +46.8% |
| ROTONDI, CONNOR JON | 1 | 0.0% | +0.0% |
| HOLLAND, PAUL J | 1 | 57.5% | +64.6% |
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.4% |
| BUCHANAN, BAILEY CHEYENNE | 1 | 42.9% | +57.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19224021 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | GOUGH, TIFFANY MAUREEN | — |
| 18704937 | Removal of micropollutants from water and installation for use therein | ROTONDI, CONNOR JON | — |
| 18282782 | METHODS FOR RECOMBINANT PROTEIN EXPRESSION IN EUKARYOTIC CELLS | HOLLAND, PAUL J | — |
| 18273501 | CRISPR-ASSOCIATED BASED-EDITING OF THE COMPLEMENTARY STRAND | VANHORN, ABIGAIL LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19224021 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | GOUGH, TIFFANY MAUREEN | — |
| 18282782 | METHODS FOR RECOMBINANT PROTEIN EXPRESSION IN EUKARYOTIC CELLS | HOLLAND, PAUL J | — |
| 18273501 | CRISPR-ASSOCIATED BASED-EDITING OF THE COMPLEMENTARY STRAND | VANHORN, ABIGAIL LOUISE | — |
| 17619773 | Type III CRISPR/Cas-based Diagnostics | BUCHANAN, BAILEY CHEYENNE | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1778 | 1 |
| 1656 | 1 |
| 1636 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19224021 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS | GOUGH, TIFFANY MAUREEN | 1651 | §101DP | Final Rejection | — | Pending | May 30, 2025 |
| 18704937 | Removal of micropollutants from water and installation for use therein | ROTONDI, CONNOR JON | 1778 | §103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18282782 | METHODS FOR RECOMBINANT PROTEIN EXPRESSION IN EUKARYOTIC CELLS | HOLLAND, PAUL J | 1656 | §102§103§112 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18273501 | CRISPR-ASSOCIATED BASED-EDITING OF THE COMPLEMENTARY STRAND | VANHORN, ABIGAIL LOUISE | 1636 | §103§112 | Final Rejection | — | Pending | Jul 20, 2023 |
| 17619773 | Type III CRISPR/Cas-based Diagnostics | BUCHANAN, BAILEY CHEYENNE | 1682 | §103 | Non-Final OA | — | Pending | Dec 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial